166 related articles for article (PubMed ID: 17593249)
1. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
[No Abstract] [Full Text] [Related]
2. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies in myelodysplastic syndromes and acute myeloid leukemias.
Morgan MA; Reuter CW
Ann Hematol; 2006 Mar; 85(3):139-63. PubMed ID: 16391911
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Ducastelle S; Adès L; Gardin C; Dombret H; Prébet T; Deconinck E; Rio B; Thomas X; Debotton S; Guerci A; Gratecos N; Stamatoullas A; Fegueux N; Dreyfus F; Fenaux P; Wattel E
Haematologica; 2006 Mar; 91(3):373-6. PubMed ID: 16531261
[TBL] [Abstract][Full Text] [Related]
5. Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
Tholouli E; Liakopoulou E; Greenfield HM; Shaw BE; Tauro S; Byrne JL; Dennis M; Burthem J; Lucas GS; Craddock C; Russell NH; Liu Yin JA
Br J Haematol; 2008 Jun; 142(2):318-20. PubMed ID: 18492100
[No Abstract] [Full Text] [Related]
6. [Acute myelogenous leukemia and myelodysplastic syndrome after treatment with cytostatic agents].
Abrahamsen AF
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2542-5. PubMed ID: 11070993
[TBL] [Abstract][Full Text] [Related]
7. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
Müller-Thomas C; Schuster T; Peschel C; Götze KS
Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
[TBL] [Abstract][Full Text] [Related]
8. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
9. Response in acute myeloid leukemia.
Estey E
Clin Adv Hematol Oncol; 2008 Feb; 6(2):113-7. PubMed ID: 18347562
[TBL] [Abstract][Full Text] [Related]
10. Clofibric acid: a potential therapeutic agent in AML and MDS.
Fenton SL; Drayson MT; Hewison M; Vickers E; Brown G; Bunce CM
Br J Haematol; 1999 May; 105(2):448-51. PubMed ID: 10233420
[TBL] [Abstract][Full Text] [Related]
11. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity.
Warlick ED; Cao Q; Miller J
Leukemia; 2013 Aug; 27(8):1789-91. PubMed ID: 23446311
[No Abstract] [Full Text] [Related]
13. Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity.
Bruserud Ø; Reikvam H
Expert Opin Ther Targets; 2010 Nov; 14(11):1139-42. PubMed ID: 20942744
[TBL] [Abstract][Full Text] [Related]
14. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
15. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
16. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Sill H; Zinke-Cerwenka W; Berghold A
Bone Marrow Transplant; 2007 Apr; 39(8):509; author reply 509-10. PubMed ID: 17322936
[No Abstract] [Full Text] [Related]
17. [Long-term remissions in postmyelodysplasia acute myeloblastic leukemia].
Olavarría E; Román A; Prieto E; Cabello A; Sánchez Fayos J
Rev Clin Esp; 1994 Jun; 194(6):511-2. PubMed ID: 8079028
[No Abstract] [Full Text] [Related]
18. Intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia.
Ferrant A; Doyen C; Bosly A; Delannoy A; Cornu G; Michaux JL
Br J Haematol; 1987 Nov; 67(3):375. PubMed ID: 3479998
[No Abstract] [Full Text] [Related]
19. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
[TBL] [Abstract][Full Text] [Related]
20. Intensive chemotherapy in myelodysplastic syndromes.
Hamblin TJ
Blood Rev; 1992 Dec; 6(4):215-9. PubMed ID: 1486290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
